Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: NOVARTIS FARMA
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
Multicenter, open label, prospective study to evaluate the efficacy and safety of deferasirox 30 mg/kg/day for 52 weeks, in transfusion-dependent &#946;-thalassemic patients with cardiac MRI T2* <20 msec
To evaluate the change in iron overload measured by cardiac MRI T2* after 52 weeks of treatment with deferasirox in &#946;-thalassemic patients affected by transfusion-dependent iron overload and ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A 52-week, international, multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of lumiracoxib 100mg od, lumiracoxib 100mg bid and celecoxib 200mg od in patients with primary osteoarthritis of hip, knee, hand or spine
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A 2-year extension to study 2203, partially randomized, double-blind, placebo-controlled in the first year and open label in the second year, to assess the safety of the dose of AAE581 selected for phase III development in postmenopausal osteoporosis, and the offset of effect on biomarkers and BMD
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A Phase Ib multicenter dose-determination study, with an adaptive, randomized, placebo-controlled, double-blind phase II, using various repeated IV doses of BHQ880 in combination with zoledronic acid in relapsed or refractory myeloma patients with prior skeletal-related event
Escalation phase (Phase I): 1. To determine the maximum-tolerated dose (MTD) and to characterize dose limiting toxicity (DLT) of escalating doses of BHQ880 (up to a maximum dose of 20 mg/kg) in combin...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A phaseI dose escalation study of AMN107 in combination with Imatinib on a continous daily dosing schedule in adult patients with Imatinib-resistent gastrointestinal stromal tumours (GIST)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A non-randomized, multiple dose, three treatment period, open-label, single sequence, single group study to evaluate the pharmacokinetic effect of two doses of QTI571 (imatinib) on the co-administered drugs sildenafil and bosentan in pulmonary arterial hypertension (PAH) patients
To investigate the effect of two dose levels of QTI571 on the pharmacokinetics of the coadministered drugs sildenafil and bosentan at steady-state in patients with pulmonary arterial hypertension.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A prospective, randomized, multi-center comparative 2-arm trial on efficacy and safety of zoledronic acid every 3-months vs. every 4 weeks beyond approximately 1 year of treatment with zoledronic acid in patients with bone lesions from breast cancer
The primary objective is to determine the efficacy skeletal morbidity rate of Zometa administered every three months versus Zometa given every 4 weeks in patients with bone metastasis from breast ca...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
Study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia
The primary objective of the study is to investigate current criteria driving re-treatment in patients affected by CNV secondary to PM and experiencing a relapse of the disease after the first adminis...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
An 8-week, randomized, double-blind, parallel-group, multicenter study assessing the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in patients 65 years of age with essential hypertension, using 24-hour ABPM, with lisinopril 10 mg as a reference
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
Multicenter, randomized, blinded, placebo controlled, cross over, single dose study to assess the effect of indacaterol (150 �g) versus tiotropium (18 �g) on Inspiratory Capacity in moderate COPD patients
To demonstrate that a single dose of indacaterol 150 &#956;g is non inferior to a single dose of tiotropium 18 &#956;g with regard to the Inspiratory Capacity (IC) peak value (defined as maxim...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
Next